BLRX - Financial Snapshot

📈 Metrics for BLRX

Price	$3.47
netCurrentAssetsPerShare	$2.03 netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
netTangibleAssetsPerShare	$2.27 netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
maxEarningPowerPerShare	$-6.84 maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
adjustedEarningPower	$-7.72 adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
nonCashChargeToMKTCAP	1.1% nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
cashValuePerShare	$1.0 cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding

Data as of: Price 11-03-25 16:00 ET, Balance Sheet 2025-06-30, Income Statement 2025-06-30

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.